Byakangelicol

Byakangelicol, isolated from Angelica dahurica, inhibits interleukin-1beta (IL-1beta) -induced prostaglandin E2 (PGE2) release in A549 cells mediated by suppression of cyclooxygenase-2 (COX-2) expression and the activity of COX-2 enzyme. Byakangelicol has therapeutic potential as an anti-inflammatory agent on airway inflammation[1].

Product Specifications

CAS Number

[26091-79-2]

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

COX

Type

Natural Products

Related Pathways

Immunology/Inflammation

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/byakangelicol.html

Purity

99.87

Solubility

DMSO : 50 mg/mL (ultrasonic)

Smiles

O=C1C=CC2=C(OC)C3=C(OC=C3)C(OC[C@@H](O4)C4(C)C)=C2O1

Molecular Formula

C17H16O6

Molecular Weight

316.31

Precautions

H302, H315, H319, H335

References & Citations

[1]Lin CH, et al. Byakangelicol, isolated from Angelica dahurica, inhibits both the activity and induction of cyclooxygenase-2 in human pulmonary epithelial cells. J Pharm Pharmacol. 2002 Sep;54 (9) :1271-8.